Large prospective trials designed to assess the relationship between metabolic control and CV outcomes in type 2 diabetes have entered a new phase of scrutiny due to strict requirements imposed by the FDA to assess new anti-diabetic agents. So what have we learned from recently completed trials and what do we expect to learn from on-going trials?
Bailey, C. J., Day, C., Campbell, I. W., & Schindler, C. (2012). Glycaemic control and cardiovascular outcome trials in type 2 diabetes. British Journal of Diabetes and Vascular Disease, 12(4), 161-164. https://doi.org/10.1177/1474651412458958